{"id":"dd52dc15-f3b2-5ebb-998b-0df68ea27f0a","stable_key":"fe6af7fc-7372-5c4f-9c2f-2bbf56695397:phosphorus-burosumab-phosphate","predicate":"increases","statement":"Across dosing-interval midpoints, 94.1% on burosumab versus 7.6% on placebo attained mean serum phosphate above the lower limit of normal.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"context_dependent","is_public":true,"mechanism_event_id":"a6a37466-cc16-5898-8fa0-f94578338f4b","mechanism_event_label":"Blocking the wasting signal substantially improved the phosphate measurement.","subject":{"id":"065e5ba3-c727-542d-8509-073417902590","slug":"burosumab","display_name":"Burosumab anti-FGF23 antibody","entity_type_key":"protein"},"object":{"id":"0e882e8c-b8c4-59e9-b756-28d37b64764e","slug":"serum-inorganic-phosphate","display_name":"Serum inorganic phosphate concentration","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"a6a37466-cc16-5898-8fa0-f94578338f4b","stable_key":"fe6af7fc-7372-5c4f-9c2f-2bbf56695397:phosphorus-burosumab-phosphate-event","event_type":"observed_intervention","label":"Blocking the wasting signal substantially improved the phosphate measurement.","description":"Across dosing-interval midpoints, 94.1% on burosumab versus 7.6% on placebo attained mean serum phosphate above the lower limit of normal.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"d083e340-fe18-504f-a680-1633caf2eca6","slug":"phex","display_name":"PHEX","entity_type_key":"protein"},"role":"underlying_disease_gene","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"6edbc5a6-fcb5-516d-9c86-66950a8984b3","slug":"fgf23","display_name":"Fibroblast growth factor 23 / FGF23","entity_type_key":"protein"},"role":"drug_target","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"065e5ba3-c727-542d-8509-073417902590","slug":"burosumab","display_name":"Burosumab anti-FGF23 antibody","entity_type_key":"protein"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""},{"entity":{"id":"0e882e8c-b8c4-59e9-b756-28d37b64764e","slug":"serum-inorganic-phosphate","display_name":"Serum inorganic phosphate concentration","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":3,"notes":""}]},"contexts":[{"dimension":"availability_state","value_text":"machinery_impairment","comparator":null,"unit":null,"notes":"Imported condition classification; unverified.","entity":null},{"dimension":"evidence_span","value_text":"{\"source_cache\": \"artifacts/phosphorus-research/29947083.abstract.txt\", \"locator\": \"Primary indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"c1b305f00a7b9a569ccd197728d942ebbf55f9eaa164a95086d69a34608d3c4e\", \"start_char\": 0, \"end_char\": 2327, \"text_sha256\": \"c1b305f00a7b9a569ccd197728d942ebbf55f9eaa164a95086d69a34608d3c4e\"}","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Randomized double-blind placebo-controlled phase 3 trial","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"Burosumab 1 mg/kg or placebo every four weeks; week-24 analysis","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"FGF23-mediated inherited disease, not simple nutritional deficiency. Pain and function outcomes require multiplicity-adjusted interpretation.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Phosphorus research collection; topical membership is not evidence of a direct dietary effect.","comparator":null,"unit":null,"notes":"","entity":{"slug":"phosphorus","display_name":"Phosphorus","entity_type_key":"nutrient_element"}},{"dimension":"organism","value_text":"Human","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"Blocking the wasting signal substantially improved the phosphate measurement.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"[phosphorus-p29947083] A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis. (2018). https://pubmed.ncbi.nlm.nih.gov/29947083/ DOI: 10.1002/jbmr.3475","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue_or_cell_type","value_text":"134 symptomatic adults with X-linked hypophosphatemia","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"trigger_kind","value_text":"machinery_impairment","comparator":null,"unit":null,"notes":"Imported condition classification; unverified.","entity":null}],"evidence":[{"id":"3ceb96ee-3440-5ee3-b292-db834becafd4","evidence_kind":"source_excerpt","locator":"Lines 1193-1204","start_line":1193,"end_line":1204,"excerpt":"### phosphorus-burosumab-phosphate\nAcross dosing-interval midpoints, 94.1% on burosumab versus 7.6% on placebo attained mean serum phosphate above the lower limit of normal.\nCondition category: machinery_impairment\nnutrient_topic: Phosphorus research collection; topical membership is not evidence of a direct dietary effect.\nplain_language: Blocking the wasting signal substantially improved the phosphate measurement.\norganism: Human\ntissue_or_cell_type: 134 symptomatic adults with X-linked hypophosphatemia\nexperimental_model: Randomized double-blind placebo-controlled phase 3 trial\nlimitations: FGF23-mediated inherited disease, not simple nutritional deficiency. Pain and function outcomes require multiplicity-adjusted interpretation.\nexposure: Burosumab 1 mg/kg or placebo every four weeks; week-24 analysis\nevidence_span: {\"source_cache\": \"artifacts/phosphorus-research/29947083.abstract.txt\", \"locator\": \"Primary indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"c1b305f00a7b9a569ccd197728d942ebbf55f9eaa164a95086d69a34608d3c4e\", \"start_char\": 0, \"end_char\": 2327, \"text_sha256\": \"c1b305f00a7b9a569ccd197728d942ebbf55f9eaa164a95086d69a34608d3c4e\"}\n[phosphorus-p29947083] A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis. (2018). https://pubmed.ncbi.nlm.nih.gov/29947083/ DOI: 10.1002/jbmr.3475","model_system":"Randomized double-blind placebo-controlled phase 3 trial","directness":"author_interpretation","verification_status":"source_derived_draft","notes":"Exact curation-document quotation, not publisher quotation. Study references: [phosphorus-p29947083] A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis. (2018). https://pubmed.ncbi.nlm.nih.gov/29947083/ DOI: 10.1002/jbmr.3475","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"cfdefe70-3a09-5e2e-97c8-46626382e4b4","stable_key":"import-fe6af7fc-7372-5c4f-9c2f-2bbf56695397","title":"Phosphorus: metabolism, signaling and nutrient connections (2026-09-17)","document_type":"imported_text","citation_label":"AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text.","file_path":"","sha256":"a04956d7177582b749608db404e6b691ae3b28a9f2f762781b6d820b461044fb","revision_id":"713b78f5-1133-5b2b-8822-20c0852e3715","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}